Pacira Pharmaceuticals, Inc. (PCRX)

Company Description

Pacira Pharmaceuticals is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the US in April 2012. EXPAREL and two other products have utilized the PCRX proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.

 

COMPANY ADDRESS
5 Sylvan Way
Parsippany, NJ 07054
United States

COMPANY PHONE
973-254 3560

COMPANY WEBSITE



Get BioInvest's perspective on Pacira's CEO


Latest Company News

Trading Sheet: Reviewing the Levels for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) The Standard - 15 hours ago Investors are constantly examining different company financial indicators to assess trading opportunities. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) presently has an EV or Enterprise Value of 1851529. The EV is used to show how the market assigns ... [...]
Thu, Apr 27, 2017 2:36:00 PM, Continue reading at the source
Pacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial ... Nasdaq - 18 hours ago PARSIPPANY, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. Pacira Pharmaceuticals Inc (PCRX) Stake Reduced by UBS Asset Management ... - The Cerbat Gem Pacira Pharmaceuticals Inc (PCRX) Expected to Announce Earnings of -$0.24 Per ... - Markets Daily [...]
Thu, Apr 27, 2017 12:00:00 PM, Continue reading at the source
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference Yahoo Finance - Apr 3, 2017 PARSIPPANY, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (PCRX) today announced that members of its management team are scheduled to present at the 16th Annual Needham Healthcare Conference at 3:00 PM ET on ... Pacira Pharmaceuticals Inc (PCRX) Given Buy Rating at Canaccord Genuity - The Cerbat Gem Its time to give a fresh look to Pacira Pharmaceuticals, Inc. (PCRX) and ... - USA Commerce Daily [...]
Mon, Apr 03, 2017 12:55:00 PM, Continue reading at the source
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare ... GlobeNewswire (press release) - Mar 13, 2017 PARSIPPANY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its management team is scheduled to present at the Barclays Global Healthcare Conference at 10:15 a.m. Pacira Pharma (PCRX): Survey Supports Strong Volume Growth For Exparel - Piper ... - StreetInsider.com [...]
Mon, Mar 13, 2017 8:02:00 PM, Continue reading at the source
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate ... GlobeNewswire (press release) - Mar 6, 2017 PARSIPPANY, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes ... Pacira prices $300M convertible debt offering - Seeking Alpha Pacira Pharmaceuticals Inc (PCRX) Downgraded by Janney Montgomery Scott - Chaffey Breeze [...]
Mon, Mar 06, 2017 9:01:00 PM, Continue reading at the source
2017 To Be A Very Eventful Year For Pacira Seeking Alpha - Jan 20, 2017 Pacira Pharmaceuticals (NASDAQ:PCRX) gave an interesting presentation at the JP Morgan Healthcare conference earlier this month. [...]
Fri, Jan 20, 2017 3:44:00 PM, Continue reading at the source
Why Pacira Pharmaceuticals, Inc. Shares Shot 17% Higher Today Fox Business - Jan 7, 2017 Pacira Pharmaceuticals markets the surgical pain medicine Exparel, and growing demand for it helped the company produce $72.9 million in revenue during the fourth quarter, according to preliminary results. Pacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million - GlobeNewswire (press release) This Top Analyst Confident on Pacira Pharmaceuticals Inc Following 2016 Pre ... - Smarter Analyst [...]
Sat, Jan 07, 2017 12:40:00 AM, Continue reading at the source
Pacira Pharmaceuticals (PCRX) Q3 2016 Results - Earnings Call Transcript Seeking Alpha - Nov 2, 2016 Please be advised that this call is being recorded at the company's request and will be archived on the company's website for two weeks from today's date. At this time, I would like to introduce Jessica Cho of Pacira Pharmaceuticals. Ma'am, you may begin. [...]
Wed, Nov 02, 2016 7:46:00 PM, Continue reading at the source
Why Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today Motley Fool - Aug 4, 2016 What: Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) are rallying 19.7% at 1:00 p.m. EDT after the company reported second-quarter financials that outpaced industry watchers' estimates. [...]
Thu, Aug 04, 2016 5:03:00 PM, Continue reading at the source
Pacira Pharmaceuticals Inc.'s Double-Digit Drop Explained Motley Fool - May 2, 2016 What: Shares of Pacira Pharmaceuticals (NASDAQ:PCRX), a specialty pharmaceutical company primarily focused on the development of medicines to help in the acute hospital care setting, dipped by as much as 10% during Monday's trading session after ... Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results - GlobeNewswire (press release) Today's Dead Cat Bounce Stock Is Pacira Pharmaceuticals (PCRX) - TheStreet.com [...]
Mon, May 02, 2016 7:52:00 PM, Continue reading at the source